AR-inhibitor Bicalutamide in Treating Patients With TNBC
Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Growing studies demonstrated that Androgen Receptor (AR) has an oncogenic role for the
patients with AR-positive Triple Negative Breast Cancer (TNBC). AR antagonists in therapy,
such as bicalutamide, completely binds to the AR, increasing AR degradation, thus are
investigated for the efficacy of the treatment of patients with AR-positive TNBC in the
study.
Phase:
Phase 2
Details
Lead Sponsor:
Jinling Hospital, China
Collaborators:
Jiangsu Province Hospital of Traditional Chinese Medicine Nanning Second People's Hospital The First People's Hospital of Lianyungang The Second Hospital of Nanjing Medical University Wenzhou Medical University Wuxi People's Hospital